2022 Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for rare

reveals mechanistic differences in regulation of the chemokine receptor CXCR4 WHIM syndrome is a rare enhanced signaling, reduced phosphorylation, β-arrestin binding and endocytosis, and a very high basal rate

Docking 490 million molecules against the σ2 receptor's AF2 model yielded a 54% hit rate, comparable to the 51% hit rate using the crystal structure. models showed some variations at key residues, and docking 1.6 billion molecules resulted in high hit rates Of 161 molecules tested, 42 substituted more than 50% of [³H]-LSD at 10 μM, achieving a 26% hit rate.

Authors Jessica S Little , Megha Tandon , Joseph Seungpyo Hong , Omar Nadeem , Adam S Sperling , Noopur Raje , Nikhil Munshi , Matthew Frigault , Sara Barmettler , Sarah P Hammond Source Contribute to the

Authors Ankit Naik , Nidhi Dalpatraj , Noopur Thakur Source Contribute to the GPCR News Coming soon Become

for Personalised Therapeutics Technologies, Chief Scientific Advisor to Dimerix, and co-founder of RAGE